Allarity Granted Japanese Patent for Stenoparib DRP Companion Diagnostic

Allarity Therapeutics announced the grant of a Japanese Patent (7917283) for its stenoparib Drug Response Predictor (DRP) companion diagnostic, extending patent protection through 2039 in Japan. The patent covers methods to predict clinical benefit from the drug, reinforcing the company's intellectual property strategy for potential commercialization.